Novo Nordisk's 4-year study on semaglutide showed patients maintained a 10.2% average weight loss and reduced the risk of stroke by 20% in overweight or obese individuals with heart disease history.

The study highlighted sustained weight loss and waist size reduction across all sexes, races, sizes, and regions for a period of up to 208 weeks.

Wegovy, containing semaglutide, mimics GLP-1 hormone and is approved for diabetes, obesity, and reducing major cardiovascular events risk.

Lesser weight loss observed in participants with a BMI under 30 kg/m2.

Study faced a 17% dropout rate due to gastrointestinal side effects, raising concerns about long-term effects and cautioning against widespread use without further research.

The findings support Novo Nordisk's push for broader insurance coverage for its weight loss drugs.